Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Statistics

Total Valuation

XENE has a market cap or net worth of $2.19 billion. The enterprise value is $1.50 billion.

Market Cap	2.19B
Enterprise Value	1.50B

Important Dates

The last earnings date was Monday, May 12, 2025, after market close.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

XENE has 76.73 million shares outstanding. The number of shares has increased by 11.90% in one year.

Current Share Class	76.73M
Shares Outstanding	76.73M
Shares Change (YoY)	+11.90%
Shares Change (QoQ)	+0.38%
Owned by Insiders (%)	0.14%
Owned by Institutions (%)	94.09%
Float	70.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	296.93
Forward PS	n/a
PB Ratio	3.10
P/TBV Ratio	3.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	200.49
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.66, with a Debt / Equity ratio of 0.01.

Current Ratio	17.66
Quick Ratio	17.43
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -31.60% and return on invested capital (ROIC) is -22.74%.

Return on Equity (ROE)	-31.60%
Return on Assets (ROA)	-22.03%
Return on Invested Capital (ROIC)	-22.74%
Return on Capital Employed (ROCE)	-41.19%
Revenue Per Employee	$22,936
Profits Per Employee	-$768,948
Employee Count	327
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-4.07M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.75% in the last 52 weeks. The beta is 1.22, so XENE's price volatility has been higher than the market average.

Beta (5Y)	1.22
52-Week Price Change	-25.75%
50-Day Moving Average	33.58
200-Day Moving Average	38.38
Relative Strength Index (RSI)	31.64
Average Volume (20 Days)	1,363,200

Short Selling Information

The latest short interest is 3.47 million, so 4.52% of the outstanding shares have been sold short.

Short Interest	3.47M
Short Previous Month	3.58M
Short % of Shares Out	4.52%
Short % of Float	4.90%
Short Ratio (days to cover)	3.78

Income Statement

In the last 12 months, XENE had revenue of $7.50 million and -$251.45 million in losses. Loss per share was -$3.22.

Revenue	7.50M
Gross Profit	-219.84M
Operating Income	-293.00M
Pretax Income	-199.34M
Net Income	-251.45M
EBITDA	-290.36M
EBIT	-293.00M
Loss Per Share	-$3.22

Balance Sheet

The company has $549.63 million in cash and $8.68 million in debt, giving a net cash position of $682.45 million or $8.89 per share.

Cash & Cash Equivalents	549.63M
Total Debt	8.68M
Net Cash	682.45M
Net Cash Per Share	$8.89
Equity (Book Value)	703.96M
Book Value Per Share	9.19
Working Capital	533.51M

Cash Flow

In the last 12 months, operating cash flow was -$196.85 million and capital expenditures -$2.93 million, giving a free cash flow of -$199.78 million.

Operating Cash Flow	-196.85M
Capital Expenditures	-2.93M
Free Cash Flow	-199.78M
FCF Per Share	-$2.60

Margins

Gross Margin	n/a
Operating Margin	-3,906.60%
Pretax Margin	-3,406.93%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

XENE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.90%
Shareholder Yield	-11.90%
Earnings Yield	-11.50%
FCF Yield	-9.14%

Analyst Forecast

The average price target for XENE is $54.82, which is 92.42% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$54.82
Price Target Difference	92.42%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XENE has an Altman Z-Score of 43.97 and a Piotroski F-Score of 1.

Altman Z-Score	43.97
Piotroski F-Score	1